Objective To update the knowledge of contact allergy to topical corticosteroids.Methods A total Of 1,822 patients,who Sufiered from inflammatory skin disorders but did not respond well to topical corticosteroids,were enrolled into this study.Patch test was performed on these subjects with corticosteroid allergens,following the standardized rocedures ecommended by the International Contact Dermatitis Research Group(ICDRG).Results Of all patients,78(4.28%)had positive patch test.Among the 78 patients,33 were males,45 females,and most were young or middle-aged.During 96-168 hours after the removal of patches,positive results Were observed in 42.31%(33/78)of the patients.Twenty eight patients had anaphy lactic reaction induced by hydrocortisone butyrate,25 by dexamethasone sodium phosphate,and 17 by triam cinolone acetonide.A correlation Between sensitizing glucocorticoids detected by patch testing and adminis trated drugs in clinic was found in 74 cases.ConclusionsContact allergy caused by topical corticosteroids is not rare,and more attention should be paid to this issue in the treatment of inflammatory skin disorders.

Objective: To investigate the efficacy and safety of the recombinant human tumor necrosis factor receptor Ⅱ-IgG Fc fusion protein (rhTNFR: Fc, etanercept) for the treatment of occupational medicamentosa-like dermatitis induced by trichloroethylene (OMLDT) . Methods: In September 2011 to February 2016, 12 patients with OMLDT were treated with etanercept 25 mg, subcutaneous injection, twice per week, doubling of first dose. The course of treatment was 6 weeks. The drug eruption area and severity index (DASI) score, the proportion of patients achieving a 50%, 75% and 90% reduction in DASI (DASI50, DASI75, DASI90) and the serum level of TNF-α were used to assess the efficacy at different times. Adverse reactions were also recorded and evaluated. The results were statistically analyzed by nonparametric Friedman test and repetitive measurement ANOVA using the software SPSS19.0. Results: After 4 weeks treatment, the DASI score decreased form 56.33±7.02 to 0.50±0.91 (P<0.01) . The DASI50, DASI75 and DASI90 were all increased to 12 (100%) . The serum level of TNF-α decreased form (43.74±41.62) pg/ml to (3.03±0.47) pg/ml (P<0.01) . Statistically significant difference was observed from the above indexes. There were no adverse reactions in clinical application. Conclusion Recombinant human tumor necrosis factor receptor Ⅱ-IgG Fc fusion protein may be a safe and effective drug in the treatment of OMLDT.